Management of Abnormal Pap Smear Results

Risk-Based Management Framework

The American Society for Colposcopy and Cervical Pathology (ASCCP) recommends a risk-based approach that combines patient-level risk data with clinical action thresholds to generate personalized recommendations based on risk for CIN 3 or worse 1

For women aged ≥25 years with ASC-US, reflex HPV DNA testing is the preferred management strategy, with colposcopy recommended if HPV positive 2, 1, 3
The American College of Obstetricians and Gynecologists recommends that women with LSIL and positive HPV test undergo colposcopy 1
The American Society for Colposcopy and Cervical Pathology (ASCCP) recommends colposcopy or expedited treatment for all women with HSIL 5, 2, 1
For women with ASC-H, colposcopy is recommended due to the intermediate risk between ASC-US and HSIL 2, 1

The American College of Obstetricians and Gynecologists recommends colposcopy for all cases of HPV 16 or 18 positive results, even if cytology is normal 6
For women aged ≥30 years with positive high-risk HPV (non-16/18) but negative cytology, repeat co-testing at 12 months is the preferred strategy 6

The American College of Obstetricians and Gynecologists recommends conservative management for women aged 21-24 years, with CIN 1 not being treated in any age group unless persistent for 2 years 5
HIV-positive women require more aggressive screening and follow-up, with cervical cytology screening twice within the first year after initial HIV diagnosis 4

The American Society for Colposcopy and Cervical Pathology (ASCCP) recommends surveillance for at least 25 years after treatment for high-grade precancer, with initial post-treatment testing including HPV test or cotest at 6, 18, and 30 months 1, 6

The American College of Obstetricians and Gynecologists recommends repeating unsatisfactory cervical cytology tests, even for women with HPV-negative results 5